Search

ENANTA PHARMACEUTICALS INC

Open

SectorGezondheidszorg

13.99 -0.07

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

13.57

Max

14.65

Belangrijke statistieken

By Trading Economics

Inkomsten

-6.4M

-20M

Verkoop

-2.8M

14M

EPS

-0.67

Winstmarge

-135.81

Werknemers

120

EBITDA

-6.8M

-15M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+41.84% upside

Dividenden

By Acuity

Volgende Winsten

13 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-27M

374M

Vorige openingsprijs

14.06

Vorige sluitingsprijs

13.99

Nieuwssentiment

By Acuity

71%

29%

311 / 340 Rangschikking in Healthcare

ENANTA PHARMACEUTICALS INC Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 aug 2026, 19:06 UTC

News

Enanta Pharmaceuticals is rising despite recent downgrades, remaining above its 20-day moving average. HC Wainwright maintains a "buy" rating with a $20 target.

21 aug 2026, 19:41 UTC

Enanta Pharmaceuticals is trading higher, supported by gains in biotechnology stocks. The asset remains above its 20-day moving average during Friday's session.

20 aug 2026, 19:31 UTC

Enanta Pharmaceuticals Inc. shares are lower today amid pressure on biotechnology stocks, continuing a decline since Wednesday's close. No specific news was identified.

18 aug 2026, 19:16 UTC

Enanta Pharmaceuticals is trading higher today, supported by a rally in the Biotechnology sub-sector. Shares have gained since Monday's close.

17 aug 2026, 20:06 UTC

Enanta Pharmaceuticals Inc shares are lower today, continuing a decline since Friday amid broader market weakness following a drop in U.S. retail sales.

14 aug 2026, 20:06 UTC

Enanta Pharmaceuticals is trading lower amid mixed market sentiment following a reported decline in U.S. retail sales for July.

13 aug 2026, 19:36 UTC

Enanta Pharmaceuticals Inc is trading higher, remaining above its 20-day moving average, despite no specific company news identified for the price movement.

11 aug 2026, 20:06 UTC

Enanta Pharmaceuticals Inc shares are lower today, reflecting broader market declines. The stock reached a session low earlier but has since recovered slightly.

5 aug 2026, 19:46 UTC

Enanta Pharmaceuticals Inc shares are lower, reflecting broader market sentiment amid disappointing ADP employment data showing a rise of only 44,000 jobs in July.

4 aug 2026, 19:46 UTC

Enanta Pharmaceuticals Inc shares are higher, buoyed by a decline in crude oil prices that eases inflation concerns. No specific company news was identified.

3 aug 2026, 19:23 UTC

Enanta Pharmaceuticals Inc shares are rising amid a broader market rally, supported by gains in major technology stocks and renewed investor confidence.

31 jul 2026, 20:06 UTC

Enanta Pharmaceuticals Inc's shares are lower today, continuing a downward trend amid rising U.S. Treasury yields and crude oil prices. No specific news was identified.

30 jul 2026, 19:45 UTC

Enanta Pharmaceuticals Inc. is advancing, supported by broader market gains. Earlier in the session, shares pulled back from a session high.

29 jul 2026, 18:26 UTC

Enanta Pharmaceuticals Inc is declining in Wednesday's session, marking the seventh consecutive day of lower prices. No specific news has been identified to explain the movement.

28 jul 2026, 20:06 UTC

Enanta Pharmaceuticals Inc is declining, marking five consecutive sessions lower. The stock peaked earlier but has since pulled back amid broader market pressures.

27 jul 2026, 18:36 UTC

Enanta Pharmaceuticals Inc is higher today, building on Friday's momentum amid broader market dynamics following a decline in oil prices.

24 jul 2026, 20:06 UTC

Enanta Pharmaceuticals Inc. shares are lower today, reversing from a recent trend of higher daily closes since Thursday's close.

21 jul 2026, 19:31 UTC

Enanta Pharmaceuticals is rising during Tuesday's session, reflecting broader market strength and positive sentiment from recent earnings reports by General Motors and Novartis.

20 jul 2026, 19:46 UTC

Enanta Pharmaceuticals Inc shares are lower today, continuing a decline since Friday's close. The stock has shown significant volatility during the session.

Peer Vergelijking

Prijswijziging

ENANTA PHARMACEUTICALS INC Prognose

Koersdoel

By TipRanks

41.84% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 20 USD  41.84%

Hoogste 20 USD

Laagste 20 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor ENANTA PHARMACEUTICALS INC - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Sentiment

By Acuity

311 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
help-icon Live chat